title: End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.
authors: Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.
authors: Warren P
authors: WP
authors: Mason
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012910:Snake Venoms / Q000627:therapeutic use*; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D012910:Snake Venoms; D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; D045643:DNA Repair Enzymes